Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12924141 | 1.00 | CA14 (0.46) | CA14HDAC6HDAC1HDAC2SSTR4 | |
| SCHEMBL12924143 | 0.98 | CA14 (0.47) | CA14HDAC6HDAC1HDAC2SSTR4 | |
| SCHEMBL16522402 | 0.94 | CA14 (0.43) | CA14HDAC6HDAC1HDAC2SSTR4 | |
| SCHEMBL3940498 | 0.93 | CA14 (0.42) | CA14HDAC6HDAC1HDAC2SSTR4 | |
| SCHEMBL31436149 | 0.93 | CA14 (0.42) | CA14HDAC6HDAC1HDAC2SSTR4 | |
| SCHEMBL4696802 | 0.90 | CA14 (0.46) | CA14HDAC6HDAC1HDAC2SSTR4 | |
| SCHEMBL2248633 | 0.90 | CA14 (0.46) | CA14HDAC6HDAC1HDAC2SSTR4 | |
| SCHEMBL17949691 | 0.90 | CA14 (0.43) | CA14HDAC6HDAC1HDAC2SSTR4 | |
| SCHEMBL31324971 | 0.88 | CA14 (0.51) | CA14HDAC6HDAC1HDAC2SSTR4 | |
| SCHEMBL1028104 | 0.88 | CA14 (0.41) | CA14HDAC6HDAC1HDAC2SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778618-A4 | SYNTHESIS OF TRIETHYLENETETRAMINES | PROTEMIX CORP LTD (NZ) | 2008-07-16 | — | — | EP | claimed |
| EP-1778618-A2 | SYNTHESIS OF TRIETHYLENETETRAMINES | Protemix Corporation Limited (NZ) | 2007-05-02 | — | — | EP | claimed |
| WO-2006027705-A2 | SYNTHESIS OF TRIETHYLENETETRAMINES | PROTEMIX CORPORATION LIMITED (NZ) | 2006-03-16 | — | — | WO | claimed |
| US-20060041170-A1 | starting the reaction of alkylating ethylenediamine with formaldehyde to form pure triethylenetetramine; salt formation of triethylenetetramine disuccinate or triethylenetetramine tetrahydrochloride | PHILERA NEW ZEALAND LIMITED (NZ) | 2006-02-23 | — | — | US | claimed |
| WO-2024018394-A1 | A PROCESS FOR THE PREPARATION OF CRYSTALLINE FORM A OF N, N'-BIS(2-AMINOETHYL)-1,2-ETHANEDIAMINE TETRAHYDROCHLORIDE | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD (IN) | 2024-01-25 | — | — | WO | disclosed |
| US-11795150-B2 | Synthesis of triethylenetetramines | PHILERA NEW ZEALAND LIMITED (NZ) | 2023-10-24 | — | — | US | disclosed |
| US-11795150-B2 | Synthesis of triethylenetetramines | PHILERA NEW ZEALAND LIMITED (NZ) | 2023-10-24 | — | — | US | disclosed |
| US-11795150-B2 | Synthesis of triethylenetetramines | PHILERA NEW ZEALAND LIMITED (NZ) | 2023-10-24 | — | — | US | disclosed |
| US-20230174459-A1 | LIPID CONTAINING FORMULATIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174459-A1 | LIPID CONTAINING FORMULATIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2023-06-08 | — | — | US | disclosed |
| US-11420931-B2 | Lipid containing formulations | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-08-23 | — | — | US | disclosed |
| US-20200361854-A1 | LIPID CONTAINING FORMULATIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-11-19 | — | — | US | disclosed |
| EP-1778618-A4 | SYNTHESIS OF TRIETHYLENETETRAMINES | PROTEMIX CORP LTD (NZ) | 2008-07-16 | — | — | EP | disclosed |
| WO-2008042973-A2 | LIPID CONTAINING FORMULATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
| WO-2007129060-A1 | TETRAHYDROPYRROLOPYRIMIDINEDIONES AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | ARGENTA DISCOVERY LIMITED (GB) | 2007-11-15 | — | — | WO | disclosed |
| EP-1778618-A2 | SYNTHESIS OF TRIETHYLENETETRAMINES | Protemix Corporation Limited (NZ) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006027705-A2 | SYNTHESIS OF TRIETHYLENETETRAMINES | PROTEMIX CORPORATION LIMITED (NZ) | 2006-03-16 | — | — | WO | disclosed |
| US-20060041170-A1 | starting the reaction of alkylating ethylenediamine with formaldehyde to form pure triethylenetetramine; salt formation of triethylenetetramine disuccinate or triethylenetetramine tetrahydrochloride | PHILERA NEW ZEALAND LIMITED (NZ) | 2006-02-23 | — | — | US | disclosed |
| EP-0934278-B1 | BIS(ACRIDINECARBOXAMIDE) AND BIS(PHENAZINECARBOXAMIDE) AS ANTITUMOUR AGENTS | XENOVA LTD (GB) | 2002-09-04 | — | — | EP | disclosed |
| US-6114332-A | BACTERICIDES | XENOVA LIMITED (GB) | 2000-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795150-B2 | Synthesis of triethylenetetramines | PNMT, TES, TPR | CA14 2476/4885HDAC6 1900/4885HDAC1 2229/4885 |
| US-20200361854-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | CA14 4481/4885HDAC6 2384/4885HDAC1 2041/4885 |
| US-20230174459-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | CA14 4481/4885HDAC6 2384/4885HDAC1 2041/4885 |
| US-11420931-B2 | Lipid containing formulations | LIPA, POLRMT, PHOSPHO1 | CA14 4481/4885HDAC6 2384/4885HDAC1 2041/4885 |
| US-20060041170-A1 | starting the reaction of alkylating ethylenediamine with formaldehyde to form pure triethylenetetramine; salt formation of triethylenetetramine disuccinate or triethylenetetramine tetrahydrochloride | TET1, TET2, TET3 | CA14 1005/4885HDAC6 595/4885HDAC1 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.